Manufacturers

MolecuLight Inc

P.O. Box M5G 1L7 , M5G 1L7 Toronto
101, College St. Suite 200 , M5G 1L7 Toronto
Canada

Telephone +1 647 3624684
Fax +1 647 3624730
info@moleculight.com

This company is co-exhibitor of
Canadian German Chamber of Industry and Commerce Inc.

Trade fair hall

  • Hall 16 / G42
 Interactive Plan

Hall map

MEDICA 2016 hall map (Hall 16): stand G42

Fairground map

MEDICA 2016 fairground map: Hall 16

Our range of products

Product categories

  • 05  Commodities and Consumer Goods
  • 05.18  Dressings for wounds

Dressings for wounds

Our products

Product category: Dressings for wounds

MolecuLight DarkDrape

For Optimal Fluorescence Imaging When Room Lights Cannot Be Turned Off.

MolecuLight DarkDrapeTM and MolecuLight AdapterTM provide an optimal environment for practitioners using MolecuLight i:XTM to visualize potentially harmful bacteria in wounds when required room lighting conditions cannot be met.

Made from a high density polyethylene material, DarkDrape features an adjustable drawstring which can be secured to the patient during fluorescence imaging.
This ensures the appropriate lighting conditions are met to precisely visualize bacterial presence in and around wounds.

MolecuLight Adapter securely attaches the DarkDrape to the MolecuLight i:X Imaging Device.

More Less

Company news

Date

Topic

Download

Sep 16, 2016

The Revolutionary MolecuLight i:X Wound Imaging Device Receives CE Mark Approval

The Revolutionary MolecuLight i:X™ Wound Imaging Device Receives CE Mark Approval

The MolecuLight i:X Imaging Device can instantly visualize potentially harmful bacteria at the point of care


TORONTO  – September 16, 2016 – MolecuLight Inc. has received CE Mark approval authorizing commercial sales in the European Union of its MolecuLight i:X Imaging Device, that is revolutionizing wound care.

The MolecuLight i:X will be making its European debut at the World Union of Healing Societies (WUWHS) World Congress, September 25-29 in Florence, Italy. The company will introduce the product to wound care clinics and hospitals across Europe, demonstrating how, with the MolecuLight i:X incorporated into their clinical assessment of wound care patients, health care professionals will have access to real-time visualization of potentially harmful bacteria immediately at the bedside.

The MolecuLight i:X uses the principle of fluorescence to capture and document either still images or videos of wounds as well as their surrounding areas where potentially harmful bacteria may be present, without the need of contrast agents. 

“This CE Mark approval is a major milestone for both our company and wound care as a whole,” says Craig Kennedy, MolecuLight’s CEO. “With our device already approved for use in Canada and now available in the EU, we believe that in time the MolecuLight i:X will become the stethoscope of wound care worldwide. We are eager to begin our commercialization efforts in Europe starting with the WUWHS Congress in Florence later this month.”

Dr. Ralph S. DaCosta, Founder, Chief Scientific Officer and Board Director adds: “By helping clinicians see potentially harmful bacteria levels in real-time at the bedside, we are advancing wound healing by providing a more personalized and effective approach. Soon, we will be including additional functionality to also easily and quickly measure wound size. All integrated on the same device.”

For more information about the MolecuLight i:X Imaging Device and the company, visit the www.moleculight.com website.

About MolecuLight
Founded in 2012, and based in Toronto, Canada, MolecuLight Inc. is a privately-owned medical imaging company delivering fluorescence image-guidance solutions that provide clinicians with new information about wound bacterial burden for better diagnostic and treatment decisions.

MolecuLight strives to become the ubiquitous name in fluorescence-guided wound imaging technologies and to serve the healthcare industry with world-class products and services while delivering value to all customers, employees and shareholders.

Media Contact:
Catherine Theodoropoulos, PhD
VP Marketing & Product Strategy
MaRS Centre, South Tower
101 College St., Suite 200
Toronto, Canada

More Less

Sep 9, 2016

MolecuLight to make its MEDICA debut featuring first-of-its-kind wound bacteria imaging device that guides care

FOR IMMEDIATE RELEASE

 MolecuLight to make its MEDICA debut featuring first-of-its-kind wound bacteria imaging device that guides care

Handheld fluorescence imaging allows bedside clinicians to instantly reveal and identify potentially harmful bacteria in wounds and chronic ulcers, speeding treatment and healing

TORONTO,  Sept. 9, 2016 – MolecuLight Inc. will make its first appearance at MEDICA, the world’s largest annual medical trade fair November 14-17 in Düsseldorf, Germany where it will feature the company’s first product, the MolecuLight i:X™. The patented portable device uses fluorescence imaging technology to visualize potentially harmful amounts of bacteria in wounds that might otherwise go unnoticed. The MolecuLight i:X camera captures real time images of bacteria without the use of contrasting agents and with no patient contact.

“It’s this ability to see and know where the bacteria are at the point of care that allows the clinician to implement more targeted treatment protocols, therefore improving the rate of wound closure,” explains Craig Kennedy, MolecuLight’s CEO.

A 2015 peer-reviewed study published by PLOS One found during a six-month trial that diabetic foot ulcers, when incorporating autofluorescence into the standard of care to accurately guide treatment, closed nine times faster. In another case study published in the International Wound Journal, researchers used the MolecuLight i:X to detect an infection hidden under the skin of a hospital patient who was about to be discharged. Had this infection not been caught prior to discharge, the patent may have had serious complications at home. 

In 2007 when working on his doctorate, MolecuLight’s founder and Chief Scientific Officer, Dr. Ralph DaCosta, accidentally discovered that bacteria can be made to fluoresce. Then, as a fully-qualified molecular imaging scientist, Dr. DaCosta went on to develop what is now the MolecuLight i:X at the Princess Margaret Cancer Centre and Techna Institute, both part of Toronto’s renowned University Health Network. The UHN is a healthcare grouping of four major hospitals and related institutes, renowned for its medical research and development.

The MolecuLight i:X is currently licensed for sale in Canada, and is being used by over 20 clinicians.

About MolecuLight:
Founded in 2012, and based in Toronto, Canada, MolecuLight Inc. is a privately-owned medical imaging company delivering fluorescence image-guidance solutions that provide clinicians with visual information about wound bacterial burden for better diagnostic and treatment decisions.

MolecuLight strives to become the ubiquitous name in fluorescence-guided wound imaging technologies and to serve the healthcare industry with world-class products and services while delivering value to all customers, employees and shareholders.
 
Note: The MolecuLight i:X Imaging Device is approved by Health Canada (Medical License #95784) for use in Canada.  The device is pending FDA De Novo clearance and CE mark approval, which lead to approved use in the United States and Europe respectively.

To learn more about MolecuLight, please visit us during MEDICA 2016 at the Ontario/Canada Pavilion, Hall 16, Booth G42.

You can also locate us in “Companies & Products" on the medica-tradefair.com portal. 

Media Contact:
Catherine Theodoropoulos, PhD
VP Marketing & Product Strategy
MaRS Centre, South Tower
101 College St., Suite 200
Toronto, ON  M5G 1L7  Canada
T: 416.673.6515
www.moleculight.com

 

 

-30-

More Less

Sep 9, 2016

MolecuLight feiert Messeeinstand auf der MEDICA: Neues bildgebendes Gerät für Wundbakterien verbessert Heilungschancen

ZUR SOFORTIGEN VERÖFFENTLICHUNG

MolecuLight feiert Messeeinstand auf der MEDICA:
Neues bildgebendes Gerät für Wundbakterien verbessert Heilungschancen

Tragbares Gerät für die Fluoreszenzanalyse ermöglicht klinischem Personal die Soforterkennung gefährlicher Bakterien in Wunden oder chronischen Geschwüren und beschleunigt so die Behandlung und Heilung.

TORONTO, 9. September 2016 - MolecuLight Inc. nimmt zum ersten Mal an der MEDICA, der größten, jährlich in Düsseldorf stattfindenden Medizinfachmesse teil. Vom 14.-17. November präsentiert das Unternehmen auf der Messe den MolecuLight i:X™. Das patentierte tragbare Gerät ist das Erstprodukt des Unternehmens. Es verwendet eine Fluoreszenz-Imaging-Technologie, um Wundbakterien sichtbar zu machen. Die MolecuLight i:X-Kamera erfasst Aufnahmen in Echtzeit und kommt ohne Kontrastmittel und Patientenkontakt aus.

„Genau direkt vor Ort zu sehen, wo sich die Bakterien befinden, ermöglicht viel gezieltere Behandlungsprotokolle und beschleunigt so die Wundheilung“, erklärt Craig Kennedy, CEO von MolecuLight.

Eine von PLOS One 2015 durchgeführte Peer-Review-Studie kam in einer sechsmonatigen Untersuchung zum Ergebnis, dass bei diabetischen Fußgeschwüren die Heilung neunmal schneller war, wenn mittels Autofluoreszenz die Behandlung entsprechend angepasst wurde. In einer weiteren Studie, die im International Wound Journal nachzulesen ist, gelang es dem MolecuLight i:X, eine unter der Haut eines Krankenhauspatienten verborgene Infektion zu erkennen, wobei der Patient kurz davor war, aus dem Krankenhaus entlassen zu werden. Wäre die Infektion nicht erkannt worden, hätte der Patient zu Hause sehr wahrscheinlich mit schweren Komplikationen kämpfen müssen. 

Dr. Ralph DaCosta, MolecuLight Gründer und Chief Scientific Officer, entdeckte 2007 während der Arbeit an seiner Promotion zufällig, dass Bakterien zum Fluoreszieren gebracht werden können. Nach Abschluss seiner Ausbildung in molekularer Bildgebung entwickelte er dann in Toronto den Vorläufer des MolecuLight i:X am Princess Margaret Cancer Centre und am Techna Institute. Beide Einrichtungen sind Teil des renommierten medizinischen UHN-Forschungsverbunds (University Health Network), der vier große Krankenhäuser und daran angegliederte Forschungsinstitute umfasst.

Der MolecuLight i:X ist zum Verkauf in Kanada zugelassen und wird bereits von mehr als 20 Klinikärzten verwendet.

Über MolecuLight:
MolecuLight Inc. ist ein 2012 gegründetes Unternehmen in Privatbesitz mit Sitz in Toronto. Das Unternehmen bietet ein Gerät zur fluoreszenzbasierten Bildgebung an, mit dem klinisches Personal visuelle Informationen über Wundbakterien für eine genauere Diagnose und verbesserte Therapieentscheidungen erhält.

Ziel von MolecuLight ist es, der führende Anbieter fluoreszenzgestützter Bildgebung in der bakteriellen Wunddiagnose zu werden. Mit erstklassigen Produkten und Dienstleistungen setzen wir darauf, Mehrwert für Kunden, Mitarbeiter und Aktionäre zu schaffen.

Hinweis: Das MolecuLight i:X-Imaging-Gerät ist vom kanadischen Gesundheitsministerium (Health Canada, Medical Licence #95784) für den Einsatz in Kanada zugelassen.  Die FDA- und CE-Zulassungen für den Einsatz in den USA bzw. Europa sind beantragt.

Wenn Sie mehr über MolecuLight erfahren wollen, besuchen Sie uns doch auf der MEDICA 2016 am Ontario-Kanada-Gemeinschaftspavillon, Halle 16, Stand G42.

Auf der MEDICA-Website www.medica-tradefair.com finden Sie uns auch unter Firmen & Produkte. 

 
Medienkontakt:
Catherine Theodoropoulos, PhD
VP Marketing & Product Strategy
MaRS Center, South Tower
101 College-St., Suite 200
Toronto, ON  M5G 1L7  Canada
T: +1.416.673.6515
www.moleculight.com

 

 

-30-

More Less

About us

Company details

MolecuLight strives to become the ubiquitous name in fluorescence-guided wound imaging technologies and to serve the healthcare industry with world-class products and services while delivering value to all customers, employees and shareholders.

MolecuLight Quality Statement
We will develop, sell and deploy products and services that exceed customer expectations, while complying with regulatory standards. MolecuLight operates under the control of an ISO 13485:2003 Quality Management System.

MolecuLight Core Values
  • Operating in an ethical manner at all times
  • Improving patient outcomes through product innovation
  • Remaining focused on customer, employee, and shareholder needs
  • Working hard and taking pride in our accomplishments
  • Valuing the contributions of each and every team member

More Less